KRAS and colorectal carcinoma: Figure 2b indicates the OS for each treatment. In the Cox multivariate regression analysis, a KRAS mutated tumor (HR 0.72, 95%CI = 0.54–0.96, p = 0.024), a curative treatment compared to chemotherapy alone (HR 0.21, 95%CI = 0.14–0.29, p < 0.001), a N2 CRC (HR 1.71, 95%CI = 1.20–2.43, p = 0.003), larger size of the liver metastases (HR 1.11, 95%CI = 1.06–1.17, p < 0.001), and elevated CEA (HR 1.00, 95%CI = 1.0–1.0, p = 0.050) were independent predictors of survival (Table 2).